SCHEMBL1447251

SCHEMBL1447251

O=[N+]([O-])c1cc(-c2ccnn2-c2cc[n+]([O-])c(F)c2)cc(O)c1O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
TTR P02766 5/20 0.35
KDM4E B2RXH2 3/20 0.34
MEN1 O00255 3/20 0.34
ALDH1A1 P00352 3/20 0.34
MAPT P10636 3/20 0.34
RECQL P46063 3/20 0.34
KMT2A Q03164 3/20 0.34
TDP1 Q9NUW8 3/20 0.34
LMNA P02545 2/20 0.34
THRB P10828 2/20 0.34
BLM P54132 2/20 0.34
POLB P06746 1/20 0.34
PKM P14618 1/20 0.34
IDO1 P14902 1/20 0.34
TDO2 P48775 1/20 0.34
CASP6 P55212 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
COMT P21964 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3583889 0.82 KDM4E (0.41) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1447333 0.79 TTR (0.36) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1446977 0.77 CRHBP (0.39) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1448392 0.77 TTR (0.40) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1447136 0.76 TTR (0.35) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1447983 0.75 COMT (0.38) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL3576463 0.75 TTR (0.38) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1447248 0.74 COMT (0.39) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL3595145 0.74 TTR (0.42) CRHBPCRHR2TTRKDM4EMEN1
SCHEMBL1447050 0.74 TTR (0.35) CRHBPCRHR2TTRKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2022-12-08 US disclosed
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2020-04-02 US disclosed
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2019-07-02 US disclosed
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & COMPANHIA, S.A. (PT) 2017-12-21 US disclosed
US-9550759-B2 Nitrocatechol derivatives as COMT inhibitors BIAL—PORTELA & CA, S.A. (PT) 2017-01-24 US disclosed
EP-1907382-B1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL PORTELA & CA SA (PT) 2015-05-27 EP disclosed
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS BIAL - PORTELA & CA, S.A. (PT) 2015-03-12 US disclosed
US-8907099-B2 Nitrocatechol derivatives as COMT inhibitors BIAL-PORTELA & CA, S.A. (PT) 2014-12-09 US disclosed
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA., S.A. (PT) 2012-08-02 US disclosed
US-8168793-B2 Nitrocatechol derivatives as COMT inhibitors PORTELA & CA., S.A. (PT) 2012-05-01 US disclosed
EP-2301934-A1 Nitrocatechol derivatives as COMT inhibitors BIAL - Portela & Ca., S.A. (PT) 2011-03-30 EP disclosed
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors PORTELA & CA., S.A. (PT) 2009-02-26 US disclosed
EP-1907382-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS Portela & C.A. S.A (PT) 2008-04-09 EP disclosed
WO-2007013830-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS PORTELA & CA. S.A. (PT) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362213-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 CRHBP 1863/4885CRHR2 1499/4885TTR 2183/4885
US-20150072977-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 CRHBP 1863/4885CRHR2 1499/4885TTR 2183/4885
US-20220388999-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 CRHBP 1626/4885CRHR2 1245/4885TTR 2123/4885
US-20090054437-A1 Nitrocatechol Derivatives as Comt Inhibitors COMT, PNMT, OPRK1 CRHBP 1863/4885CRHR2 1499/4885TTR 2183/4885
US-10336740-B2 Nitrocatechol derivatives as COMT inhibitors COMT, PNMT, OPRK1 CRHBP 1863/4885CRHR2 1499/4885TTR 2183/4885
US-20200102295-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 CRHBP 1626/4885CRHR2 1245/4885TTR 2123/4885
US-20120196904-A1 NITROCATECHOL DERIVATIVES AS COMT INHIBITORS COMT, PNMT, OPRK1 CRHBP 1863/4885CRHR2 1499/4885TTR 2183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.